Effect of Pro-Kinetic Drugs on Post –Prandial Glycaemic Surge in Type 2 Diabetic Patients

Effect of Pro-Kinetic Drugs on Post –Prandial Glycaemic Surge in Type 2 Diabetic Patients

Background: To study the effects of pro-kinetic agents on post-prandial glycaemia in type 2 diabetes mellitus. Methods :In this comparative study one hundred and eighty patients with Type 2 diabetes mellitus and features of gastroparesis were randomly recruited. They were divided randomly into two g...

Full description

Bibliographic Details
Main Author:	Asim Zulfiqar
Format:	Article
Language:	English
Published:	Rawalpindi Medical University 2012-12-01
Series:	Journal of Rawalpindi Medical College
Subjects:	ncretin Glucagon like Peptide
Online Access:	https://www.journalrmc.com/index.php/JRMC/article/view/558

Similar Items

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
by: Antza C, et al.
Published: (2019-08-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes
by: Yunbo Jia, et al.
Published: (2022-06-01)

Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development
by: Bo Ahrén
Published: (2019-03-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

Relationship between diet/exercise and pharmacotherapy to enhance the GLP‐1 levels in type 2 diabetes
by: Yuki Fujiwara, et al.
Published: (2019-07-01)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis
by: Eiichi Araki, et al.
Published: (2022-12-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
by: Ekaterina V. Tikhonenko, et al.
Published: (2018-12-01)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
by: Jonas Ronn, et al.
Published: (2017-12-01)

Glycemic and Metabolic Effects of Two Long Bouts of Moderate-Intensity Exercise in Men with Normal Glucose Tolerance or Type 2 Diabetes
by: Saeed Reza Eshghi, et al.
Published: (2017-07-01)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
by: Manige Konig, et al.
Published: (2021-09-01)

The effect of metformin treatment on the level of GLP-1, NT-proBNP and endothelin-1 in patients with type 2 diabetes mellitus
by: L.K. Sokolova, et al.
Published: (2020-11-01)

CORRELATION BETWEEN PRE AND POSTOPERATIVE LEVELS OF GLP-1/GLP-2 AND WEIGHT LOSS AFTER ROUX-EN-Y GASTRIC BYPASS: A PROSPECTIVE STUDY
by: Everton CAZZO, et al.
Published: (2016-12-01)

Pleiotropic effects of incretins
by: Vishal Gupta
Published: (2012-01-01)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
by: Yumie Takeshita, et al.
Published: (2022-06-01)

Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real‐world clinical practice: 36 month post‐marketing observational study
by: Rina Chin, et al.
Published: (2023-02-01)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
by: Nina A. Petunina, et al.
Published: (2018-09-01)

The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes
by: Soyeon Yoo, et al.
Published: (2021-06-01)

Effectiveness of Oral versus Injectable Semaglutide in Adults with Type 2 Diabetes: Results from a Retrospective Observational Study in Croatia
by: Sanja Klobučar, et al.
Published: (2024-02-01)

Correlation of Glypican-4 Level with Basal Active Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes Mellitus
by: Sang Ah Lee, et al.
Published: (2016-09-01)

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
by: Tina Zimmermann, et al.
Published: (2022-12-01)

Implications of Postprandial Hyperglycaemia and Role of Voglibose in Type 2 Diabetes Mellitus
by: S R Pattanaik, et al.
Published: (2018-04-01)

Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon‐like peptide‐1 receptor agonists
by: Megumi Shiomi, et al.
Published: (2019-03-01)

Human islets contain a subpopulation of glucagon-like peptide-1 secreting α cells that is increased in type 2 diabetes
by: Scott A. Campbell, et al.
Published: (2020-09-01)

Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice
by: Yangzhao Zhou, et al.
Published: (2023-09-01)

Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells
by: Yun Kyung Jeon, et al.
Published: (2014-12-01)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
by: Takaaki Murakami, et al.
Published: (2020-11-01)

Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis
by: Mahmoud M. Ali, et al.
Published: (2022-04-01)

Dietary Mannoheptulose Increases Fasting Serum Glucagon Like Peptide-1 and Post-Prandial Serum Ghrelin Concentrations in Adult Beagle Dogs
by: Leslie L. McKnight, et al.
Published: (2015-06-01)

Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4
Published: (2010-09-01)

New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
by: Won-Young Lee
Published: (2017-02-01)

Fasting GLP-1 Levels and Albuminuria Are Negatively Associated in Patients with Type 2 Diabetes Mellitus
by: Cheol-Won Jang, et al.
Published: (2024-03-01)

Renal experiences of bariatric surgery in patients with type 2 diabetes mellitus
by: I I Larina, et al.
Published: (2018-10-01)

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Liraglutide; A New Hope for Obese Diabetics
by: Ajeet Kumar, et al.
Published: (2020-12-01)

LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST
by: S. V. Nedogoda
Published: (2018-05-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)